Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2017Haemophilia

Measuring FVIII activity of glycopegylated recombinant factor VIII, N8‐GP, with commercially available one‐stage clotting and chromogenic assay kits: a two‐centre study

View Full Paper
Ask AI
Bookmark
Share

Authors

AHAndreas HillarpLund UniversityABAnnette BowyerRoyal Hallamshire HospitalMEMirella EzbanNovo Nordisk (Denmark)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hillarp et al. (2017) studied this question.

synapsesocial.com/papers/6a7d016f2d005ba2c41cc376https://doi.org/10.1111/hae.13168
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Influence of phospholipids on the assessment of factor VIII activity1998 · 118 citations
  2. 2In vivo recovery with products of very high purity — assay discrepancies1998 · 44 citations
  3. 3A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models2013 · 116 citations
  4. 4International comparative field study of N8 evaluating factor VIII assay performance2011 · 67 citations
  5. 5Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis2012 · 160 citations